$ALT News

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune: Pemvidutide Performs, But A Long Wait Ahead

Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ...

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune Q2 Earnings Call Highlights

Altimmune, Inc. Q2 2026 Earnings Call Summary

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff

Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial

Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10%

Altimmune Shares Jump After Positive Phase 2 Alcohol Use Disorder Trial Results

Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript

Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder - Slideshow

Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Altimmune Says Topline Data From RECLAIM Phase 2 Trial Of Pemvidutide For Alcohol Use Disorder Met Its Primary Endpoint Showing Statistically Significant Reduction In Heavy Drinking Days Vs. Placebo

Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market